JP2001523712A5 - - Google Patents

Download PDF

Info

Publication number
JP2001523712A5
JP2001523712A5 JP2000521818A JP2000521818A JP2001523712A5 JP 2001523712 A5 JP2001523712 A5 JP 2001523712A5 JP 2000521818 A JP2000521818 A JP 2000521818A JP 2000521818 A JP2000521818 A JP 2000521818A JP 2001523712 A5 JP2001523712 A5 JP 2001523712A5
Authority
JP
Japan
Prior art keywords
cycloalkyl
pharmaceutically acceptable
general formula
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2000521818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001523712A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/023482 external-priority patent/WO1999026616A1/en
Publication of JP2001523712A publication Critical patent/JP2001523712A/ja
Publication of JP2001523712A5 publication Critical patent/JP2001523712A5/ja
Abandoned legal-status Critical Current

Links

JP2000521818A 1997-11-25 1998-11-04 Pde−ivのベンゼンスルホンアミド阻害剤およびそれらの治療的使用 Abandoned JP2001523712A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6694397P 1997-11-25 1997-11-25
US60/066,943 1997-11-25
PCT/US1998/023482 WO1999026616A1 (en) 1997-11-25 1998-11-04 Benzenesulfonamide inhibitors of pde-iv and their therapeutic use

Publications (2)

Publication Number Publication Date
JP2001523712A JP2001523712A (ja) 2001-11-27
JP2001523712A5 true JP2001523712A5 (enExample) 2006-01-05

Family

ID=22072726

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000521818A Abandoned JP2001523712A (ja) 1997-11-25 1998-11-04 Pde−ivのベンゼンスルホンアミド阻害剤およびそれらの治療的使用

Country Status (15)

Country Link
US (1) US6162830A (enExample)
EP (1) EP1045690B1 (enExample)
JP (1) JP2001523712A (enExample)
KR (1) KR20010024268A (enExample)
AT (1) ATE238048T1 (enExample)
AU (1) AU751453C (enExample)
BR (1) BR9812527A (enExample)
CA (1) CA2299399C (enExample)
DE (1) DE69813895T2 (enExample)
DK (1) DK1045690T3 (enExample)
ES (1) ES2195419T3 (enExample)
NZ (1) NZ502965A (enExample)
PT (1) PT1045690E (enExample)
WO (1) WO1999026616A1 (enExample)
ZA (1) ZA9810735B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US6699890B2 (en) 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
JP3940290B2 (ja) * 2000-12-22 2007-07-04 ザ・ヨルダニアン・フアーマシユーテイカル・エム・エフ・ジー・アンド・メデイカル・イクイツプメント・カンパニー・リミテツド 新規化合物
SE0004780D0 (sv) 2000-12-22 2000-12-22 Jordanian Pharmaceutical Mfg & Novel compunds
US7205320B2 (en) * 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
WO2003063796A2 (en) * 2002-01-30 2003-08-07 Tularik Inc. Heterocyclic arylsulfonamidobenzylic compounds
JP4434744B2 (ja) * 2002-01-30 2010-03-17 アムジェン インコーポレイテッド アリールスルホンアミドベンジル化合物
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CA2481387A1 (en) 2002-04-12 2003-10-23 Celgene Corporation Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
ES2195785B1 (es) * 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
BR0313000A (pt) * 2002-07-19 2005-07-12 Memory Pharm Corp Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente
EP1539697A1 (en) 2002-07-19 2005-06-15 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
CN100513397C (zh) * 2002-11-19 2009-07-15 记忆药物公司 磷酸二酯酶4抑制剂
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
MXPA06001566A (es) * 2003-08-12 2006-05-15 Amgen Inc Compuestos arilsulfonamidobencilicos.
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
ES2251866B1 (es) * 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2320954B1 (es) * 2007-03-02 2010-03-16 Laboratorio Almirall S.A. Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
MX2010010334A (es) * 2008-03-24 2010-10-08 Celgene Corp Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
WO2010003084A2 (en) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
FR2962649B1 (fr) * 2010-07-19 2025-10-24 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
CN111925313B (zh) * 2020-09-22 2021-06-25 纳兰迦(上海)生物医药科技有限公司 具有pde4抑制活性的化合物、制备方法、组合物及用途
JP7769365B2 (ja) * 2021-09-22 2025-11-13 日本メナード化粧品株式会社 皮膚幹細胞増殖促進剤及び皮膚再生促進剤
EP4197318B1 (en) * 2021-12-17 2025-11-19 Albert-Ludwigs-Universität Freiburg Phosphodiesterases inhibitors to promote in vitro plant cell reprogramming towards plant embryogenesis or microcallus formation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
EP0652868B1 (en) * 1992-07-28 2004-11-10 Aventis Pharma Limited INHIBITORS OF c-AMP PHOSPHODIESTERASE
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5728712A (en) * 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU5772296A (en) * 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
WO1996036596A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
US5834485A (en) * 1996-05-20 1998-11-10 Chiroscience Limited Quinoline sulfonamides and their therapeutic use

Similar Documents

Publication Publication Date Title
JP2001523712A5 (enExample)
WO2006060029A3 (en) Insecticidal n-substituted sulfoximines
JP2002501057A5 (enExample)
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
JP2004530641A5 (enExample)
NZ541974A (en) Nucleotide phosphoramidates as anticancer agents
CA2470183C (en) Intermediates for preparing arylsulphonamides and analogues
JP2002543183A5 (enExample)
JP2003531118A5 (enExample)
AP2000001786A0 (en) Therapeutic uses of quinoline derivatives.
WO2001087845A3 (en) N-containing heterocyclic compounds and their use as 5-ht antagonists
JPH10130104A5 (enExample)
EP1331005A4 (en) MEDICINAL COMPOSITIONS FOR CONCUMITANT USE AS ANTI-CANCER AGENT
KR970704697A (ko) 2-[(디히드로)피라졸릴-3'-옥시메틸렌] 아닐리드의 살충제 및 살진균제로서의 용도 (Use of 2-[(Dihydro)Pyrazolyl-3'-Oxymethylene]-Anilides as Pest-Control Agents and Fungicides)
JP2002510633A5 (enExample)
EP1191614A3 (en) Luminescence device and metal coordination compound therefor
BR0210078A (pt) Composto, uso do mesmo, e, formulação farmacêutica
GEP20074099B (en) 3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
DE69840645D1 (en) Benzamidinderivate
JPH1180090A5 (enExample)
CO5611143A2 (es) Profarmacos de fosfatos de fluorooxindoles
JP2009538336A5 (enExample)
JP2002155281A5 (enExample)
CA2013599A1 (en) Aryl-substituted rhodanine derivatives
EP0671390A3 (en) Antithrombotic agents